Costs Along the TB Diagnostic Pathway in Uganda

Overview

Journal Int J Tuberc Lung Dis

Specialty Pulmonary Medicine

Date 2021 Jan 1

PMID 33384046

Citations 3

Authors

A Tucker

D Oyuku

T Nalugwa

M Nantale

O Ferguson

K Farr

T F Reza

P B Shete

A Cattamanchi

D W Dowdy

H Sohn

A Katamba

Affiliations

Soon will be listed here.

Citing Articles

Cost-effectiveness of integrating paediatric tuberculosis services into child healthcare services in Africa: a modelling analysis of a cluster-randomised trial.

Mafirakureva N, Denoeud-Ndam L, Tchounga B, Otieno-Masaba R, Herrera N, Mukherjee S BMJ Glob Health. 2024; 9(12.

PMID: 39694623 PMC: 11667313. DOI: 10.1136/bmjgh-2024-016416.

Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing.

Malhotra A, Thompson R, De Vos M, David A, Schumacher S, Sohn H PLoS One. 2023; 18(8):e0290496.

PMID: 37616318 PMC: 10449112. DOI: 10.1371/journal.pone.0290496.

Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.

Thompson R, Nalugwa T, Oyuku D, Tucker A, Nantale M, Nakaweesa A Lancet Glob Health. 2023; 11(2):e278-e286.

PMID: 36669808 PMC: 9848406. DOI: 10.1016/S2214-109X(22)00509-5.

References

Mugambi M, Peter T, F Martins S, Giachetti C . How to implement new diagnostic products in low-resource settings: an end-to-end framework. BMJ Glob Health. 2018; 3(6):e000914. PMC: 6254739. DOI: 10.1136/bmjgh-2018-000914. View

Raizada N, Sachdeva K, Sreenivas A, Vadera B, Gupta R, Parmar M . Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS One. 2014; 9(2):e89301. PMC: 3935858. DOI: 10.1371/journal.pone.0089301. View

Kiyaga C, Sendagire H, Joseph E, McConnell I, Grosz J, Narayan V . Uganda's new national laboratory sample transport system: a successful model for improving access to diagnostic services for Early Infant HIV Diagnosis and other programs. PLoS One. 2013; 8(11):e78609. PMC: 3827263. DOI: 10.1371/journal.pone.0078609. View

Clarke-Deelder E, Vassall A, Menzies N . Estimators Used in Multisite Healthcare Costing Studies in Low- and Middle-Income Countries: A Systematic Review and Simulation Study. Value Health. 2019; 22(10):1146-1153. PMC: 6859917. DOI: 10.1016/j.jval.2019.05.007. View

Pallas S, Courey M, Hy C, Killam W, Warren D, Moore B . Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis. Appl Health Econ Health Policy. 2018; 16(4):537-548. PMC: 6050005. DOI: 10.1007/s40258-018-0397-3. View

Engel N, Wachter K, Pai M, Gallarda J, Boehme C, Celentano I . Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform. BMJ Glob Health. 2017; 1(4):e000132. PMC: 5321377. DOI: 10.1136/bmjgh-2016-000132. View

Hsiang E, Little K, Haguma P, Hanrahan C, Katamba A, Cattamanchi A . Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness. Int J Tuberc Lung Dis. 2016; 20(9):1212-8. PMC: 5018405. DOI: 10.5588/ijtld.16.0200. View

Walker D, Kumaranayake L . Allowing for differential timing in cost analyses: discounting and annualization. Health Policy Plan. 2002; 17(1):112-8. DOI: 10.1093/heapol/17.1.112. View

Pooran A, Theron G, Zijenah L, Chanda D, Clowes P, Mwenge L . Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. Lancet Glob Health. 2019; 7(6):e798-e807. PMC: 7197817. DOI: 10.1016/S2214-109X(19)30164-0. View

10.

Sohn H, Kasaie P, Kendall E, Gomez G, Vassall A, Pai M . Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. BMC Med. 2019; 17(1):155. PMC: 6683370. DOI: 10.1186/s12916-019-1384-8. View

11.

Reza T, Nalugwa T, Farr K, Nantale M, Oyuku D, Nakaweesa A . Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). Implement Sci. 2020; 15(1):24. PMC: 7171793. DOI: 10.1186/s13012-020-00988-y. View

12.

Tampi R, Tembo T, Mukumba-Mwenechanya M, Sharma A, Dowdy D, Holmes C . Operational characteristics of antiretroviral therapy clinics in Zambia: a time and motion analysis. BMC Health Serv Res. 2019; 19(1):244. PMC: 6480736. DOI: 10.1186/s12913-019-4096-z. View

13.

Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger C, Boehme C . Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?. Eur Respir J. 2016; 48(2):516-25. PMC: 4967565. DOI: 10.1183/13993003.00543-2016. View

14.

Creswell J, Codlin A, Andre E, Micek M, Bedru A, Carter E . Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis. 2014; 14:2. PMC: 3898850. DOI: 10.1186/1471-2334-14-2. View